BRPI0518209A - agentes de ligação especìficos à angiopoietina-2 - Google Patents

agentes de ligação especìficos à angiopoietina-2

Info

Publication number
BRPI0518209A
BRPI0518209A BRPI0518209-3A BRPI0518209A BRPI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A
Authority
BR
Brazil
Prior art keywords
specific binding
binding agents
angiopoietin
antibodies
disclosed
Prior art date
Application number
BRPI0518209-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel Jonathon Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0518209A publication Critical patent/BRPI0518209A/pt

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0518209-3A 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2 BRPI0518209A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (fr) 2004-10-19 2005-10-19 Agents de liaison specifiques de l'angiopoietine-2

Publications (1)

Publication Number Publication Date
BRPI0518209A true BRPI0518209A (pt) 2008-11-04

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518209-3A BRPI0518209A (pt) 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2

Country Status (10)

Country Link
JP (2) JP2008520188A (fr)
CN (1) CN101495513B (fr)
BR (1) BRPI0518209A (fr)
EA (1) EA011866B1 (fr)
IL (1) IL182279A0 (fr)
MA (1) MA29015B1 (fr)
MX (1) MX2007004247A (fr)
RU (2) RU2404992C2 (fr)
SG (1) SG156668A1 (fr)
ZA (1) ZA200704020B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
HUE034044T2 (en) * 2011-09-30 2018-01-29 Dana Farber Cancer Inst Inc Therapeutic peptides
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2014100834A1 (fr) * 2012-12-21 2014-06-26 The Regents Of The University Of California Méthodes et compositions pour le traitement de la toxicité du cyanure et de sulfure d'hydrogène
NZ714049A (en) * 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241380T1 (de) * 1999-03-26 2003-06-15 Regeneron Pharma Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU784231B2 (en) * 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ATE536868T1 (de) * 2001-10-12 2011-12-15 Monosolrx Llc Einheitliche filme als schnell auflösende verabreichungsformen enthaltend geschmacksmaskiereden stoff
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
MX2007004247A (es) 2007-06-12
EA011866B1 (ru) 2009-06-30
JP2011207882A (ja) 2011-10-20
CN101495513A (zh) 2009-07-29
ZA200704020B (en) 2008-06-25
CN101495513B (zh) 2014-08-06
SG156668A1 (en) 2009-11-26
IL182279A0 (en) 2007-07-24
MA29015B1 (fr) 2007-11-01
RU2010132956A (ru) 2012-02-10
RU2007118670A (ru) 2008-12-27
EA200700876A1 (ru) 2007-10-26
JP2008520188A (ja) 2008-06-19
RU2404992C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
BRPI0518209A (pt) agentes de ligação especìficos à angiopoietina-2
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA200800812A1 (ru) Композиции антитела против cd3
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA201070888A1 (ru) Антитела и их производные
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
MX2007013759A (es) Agentes de union de esclerostina.
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
CL2012000631A1 (es) Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico.
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.